Work

A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma

Year: 2010

Type: article

Study design: Clinical Trial

Source: Cancer Chemotherapy and Pharmacology

DOI: 10.1007/s00280-010-1320-2

Authors: Fumihiko Kanai, Haruhiko Yoshida, Ryosuke Tateishi, Shinpei Sato, Takao Kawabe, Shuntaro Obi, Yuji Kondo, Makoto Taniguchi, Kazumi Tagawa, Masafumi Ikeda, Chigusa Morizane, Takuji Okusaka, Hitoshi Arioka, Shuichiro Shiina, Masao Omata

Institutions: The University of Tokyo, Mitsui Memorial Hospital, National Cancer Center Hospital, Yokohama Rosai Hospital

Language: English

Topic: Hepatocellular Carcinoma Treatment and Prognosis

Subfield: Hepatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: Taiho Pharmaceutical

OpenAlex ID: W2016364458

FWCI: 10.55

Cites: 34

Cited by: 98

Related to: 10